Skip to main content
SpringerLink
Log in

Significance of the duration of nephropathy for achieving clinical remission in patients with IgA nephropathy treated by tonsillectomy and steroid pulse therapy

  • Original Article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Background

Because of the well-established annual urinalysis screening system in Japan, the duration of nephropathy (DN) can be estimated in more than half of all patients with IgA nephropathy (IgAN). Treatment using a combination of tonsillectomy and steroid pulse (TSP) therapy has been reported as an effective method for obtaining clinical remission (CR), defined as negative hematuria and proteinuria, in IgAN patients. The present study aims to identify the correlation between DN and CR rate in IgAN patients treated by TSP therapy.

Methods

We retrospectively investigated 830 IgAN patients who were followed up for 81.6 months after TSP therapy. DN could be estimated in 495 of the 830 patients.

Results

The CR rate among patients with DN ≤36 months was 87.3% (295/338 patients). The CR rate among patients with DN of 37–84 months was 73.3% (63/86 patients), while that among patients with DN ≥85 months was 42.3% (30/71 patients). The CR rate among the remaining 335 patients in whom DN could not be estimated because of missing annual urinalysis results was 43.6% (146/335 patients). A multivariate Cox regression model using data from the former group of 495 patients showed that DN ≤36 months was a significant predictor of CR (hazard ratio 1.839; 95% confidence interval 1.410–2.398; P < 0.001).

Conclusion

Shorter DN is associated with higher likelihood of clinical remission in IgAN patients treated by TSP therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. D’Amico G, Imbasciati E, Barbiano Di Belgioioso G, Bertoli S, Fogazzi G, Ferrario F, et al. Idiopathic IgA mesangial nephropathy. Clinical and histological study of 374 patients. Medicine. 1985;64:49–60.

    PubMed  Google Scholar 

  2. Levy M, Berger J. Worldwide perspective of IgA nephropathy. Am J Kidney Dis. 1988;12:340–7.

    PubMed  CAS  Google Scholar 

  3. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med. 2002;347:738–48.

    Article  PubMed  CAS  Google Scholar 

  4. D’Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000;36:227–37.

    Article  PubMed  Google Scholar 

  5. Geddes CC, Rauta V, Gronhagen-Riska C, Bartosik LP, Jardine AG, Ibels LS, et al. A tricontinental view of IgA nephropathy. Nephrol Dial Transplant. 2003;18:1541–8.

    Article  PubMed  Google Scholar 

  6. Barratt J, Feehally J. Treatment of IgA nephropathy. Kidney Int. 2006;69:1934–8.

    Article  PubMed  CAS  Google Scholar 

  7. Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol. 2005;16:2088–97.

    Article  PubMed  CAS  Google Scholar 

  8. Shu KH, Ho WL, Lu YS, Cheng CH, Wu MJ, Lian JD. Long-term outcome of adult patients with minimal urinary abnormalities and normal renal function. Clin Nephrol. 1999;52:5–9.

    PubMed  CAS  Google Scholar 

  9. Sezto CC, Lai FM, To KF, Wong TY, Chow KM, Choi PC, et al. The natural history of immunoglobulin A nephropathy among patients with hematuria and minimal proteinuria. Am J Med. 2001;110:434–7.

    Article  Google Scholar 

  10. Shen P, He L, Li Y, Wang Y, Chan M. Natural history and prognostic factors of IgA nephropathy presented with isolated microscopic hematuria in Chinese patients. Nephron Clin Pract. 2007;106:c157–61.

    Article  PubMed  CAS  Google Scholar 

  11. Koyama A, Igarashi M, Kobayashi M. Members and Coworkers of the Research Group on progressive renal diseases. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Am J Kidney Dis. 1997;29:526–32.

    Article  PubMed  CAS  Google Scholar 

  12. Health and welfare statistics association. 2004 statistical abstracts on health and welfare in Japan. In: Statistical abstracts on health and welfare in Japan 2006. Health and welfare statistics association; 2006.

  13. Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–43.

    Article  PubMed  CAS  Google Scholar 

  14. Komatsu H, Fujimoto S, Hara S, Sato Y, Yamada K, Kitamura K. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol. 2008;3:1301–7.

    Article  PubMed  CAS  Google Scholar 

  15. Suwa N, Takahashi T. Morphological and morphometrical analysis of circulation in hypertension and ischemic kidney. München-Berlin-Wien: Urban & Schwarzenberg; 1971. p. 108–116.

  16. Ootaka T, Suzuki M, Sudo K, Sato H, Seino J, Saito T, et al. Histological localization of terminal complement complexes in renal diseases: an immunohistochemical study. Am J Clin Pathol. 1989;91:144–51.

    PubMed  CAS  Google Scholar 

  17. Hotta O, Taguma Y, Kurosawa K, Sudo K, Suzuki K, Horigome I. Predictive value of small crescents in IgA nephropathy: analysis of four patients showing a deteriorated renal function during a long follow-up period. Clin Nephrol. 1993;40:125–30.

    PubMed  CAS  Google Scholar 

  18. Sato Y, Hotta O, Taguma Y, Takasaka T, Nose M. IgA nephropathy with poorly development lymphoepithelial symbiosis of the palatine tonsils. Nephron. 1996;74:301–8.

    Article  PubMed  CAS  Google Scholar 

  19. Schena FP. A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med. 1990;89:209–15.

    Article  PubMed  CAS  Google Scholar 

  20. Hall CL, Bradley R, Kerr A, Attoti R, Peat D. Clinical value of renal biopsy in patients with asymptomatic microscopic hematuria with and without low-grade proteinuria. Clin Nephrol. 2004;62:267–72.

    PubMed  CAS  Google Scholar 

  21. Hotta O. Use of corticosteroids, other immunosuppressive therapies, and tonsillectomy in the treatment of IgA nephropathy. Seminars in Nephrol. 2004;24:244–55.

    Article  CAS  Google Scholar 

  22. Droz D, Kramar A, Nawar T, Noël LH. Primary IgA nephropathy: prognostic factors. Contrib Nephrol. 1984;40:202–7.

    PubMed  CAS  Google Scholar 

  23. Nicholls KM, Fairley KF, Downling JP, Kincaid-Smith P. The clinical course of mesangial IgA associated nephropathy in adults. Q J Med. 1984;53:227–50.

    PubMed  CAS  Google Scholar 

  24. Beukhof JR, Kardaun O, Schaafsma W, Poortema K, Donker AJ, Hoedemaeker PJ, et al. Toward individual prognosis of IgA nephropathy. Kidney Int. 1986;29:549–56.

    Article  PubMed  CAS  Google Scholar 

  25. Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis. 1997;29:829–42.

    Article  PubMed  CAS  Google Scholar 

  26. Frimat L, Briançon S, Hestin D, Aymard B, Renoult E, Cao Huu T, Kessler M. IgA nephropathy: prognostic classification of end-stage renal failure. L’Association des Néphrologues de l’Est. Nephrol Dial Transplant. 1997;12:2569–75.

    Article  PubMed  CAS  Google Scholar 

  27. Kobayashi Y, Kokubo T, Horii A, Hiki Y, Tateno S. Prognostic prediction of long-term clinical courses in individual IgA nephropathy patients. Nephrology. 1997;3:35–40.

    Article  Google Scholar 

  28. Reich HN, Troyanov S, Scholey JW, Cattran DC, Toronto Glomerulonephritis Registry. Remission of proteinuria improved prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18:3177–83.

    Article  PubMed  CAS  Google Scholar 

  29. Radford MG, Donadio JV, Bergstralh EJ, Grande JP. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol. 1997;8:199–207.

    PubMed  Google Scholar 

  30. Donadio JV, Bergstralth EJ, Offord KP, Holley KE, Spencer DC. Clinical and histopathologic associations with impaired renal function in IgA nephropathy. Mayo Nephrology Collaborative Group. Clin Nephrol. 1994;41:65–71.

    PubMed  CAS  Google Scholar 

  31. Bartosik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IgA nephropathy. Am J Kidney Dis. 2001;38:728–35.

    Article  PubMed  CAS  Google Scholar 

  32. Feehally J. Predicting prognosis in IgA nephropathy. Am J Kidney Dis. 2001;38:881–3.

    Article  PubMed  CAS  Google Scholar 

  33. Lee HS, Lee MS, Lee SM, Lee SY, Lee ES, Lee EY, et al. Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee’s glomerular grading system. Nephrol Dial Transplant. 2005;20:342–8.

    Article  PubMed  Google Scholar 

  34. Feriozzi S, Pierucci A, Roscia E, Cinotti GA, Pecci G. Angiotensin converting enzyme inhibition delays the progression of chronic renal failure in hypertensive patients with immunoglobulin A nephropathy. J Hypertens. 1989;7:S63–4.

    CAS  Google Scholar 

  35. Remuzzi A, Perticucci E, Ruggeneti P, Mosconi L, Limonta M, Remuzzi G. Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int. 1991;39:1247–73.

    Google Scholar 

  36. Rekola S, Bergstrand A, Butch H. Deterioration rate in hypertensive IgA nephropathy: comparison of a converting enzyme inhibitor and beta-blocking agents. Nephron. 1991;59:57–60.

    Article  PubMed  CAS  Google Scholar 

  37. Maschio G, Cagnoli L, Claroni F, Fusaroli M, Rugiu C, Sanna G, et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant. 1994;9:265–9.

    PubMed  CAS  Google Scholar 

  38. Cattran D, Greenwood BS, Math M, Ritchie MD. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis. 1994;23:247–54.

    PubMed  CAS  Google Scholar 

  39. Lewis EJ, Hunsicker L, Bain RP, Rhode RP, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–62.

    Article  PubMed  CAS  Google Scholar 

  40. The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on declining in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857–63.

    Article  Google Scholar 

  41. Appel GB, Waldman M. The IgA nephropathy treatment dilemma. Kidney Int. 2006;69:1939–44.

    Article  PubMed  CAS  Google Scholar 

  42. Rauta V, Finne P, Fagerudd J, Rosenlöf K, Törnroth T, Grönhagen-Riska C. Factors associated with progression of IgA nephropathy are related to renal function—a model for estimating risk of progression in mild disease. Clin Nephrol. 2002;58:85–94.

    PubMed  CAS  Google Scholar 

  43. Hotta O, Furuta T, Chiba S, Tomioka S, Taguma Y. Regression of IgA nephropathy: a repeat biopsy study. Am J Kidney Dis. 2002;39:493–502.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors have declared that no conflict of interest exists.

Author information

Authors and Affiliations

  1. Department of Nephrology, Sendai Shakaihoken Hospital, Tsutsumimachi 3-16-1, Aoba-ku, Sendai, Miyagi, 981-8501, Japan

    Norio Ieiri, Osamu Hotta, Toshinobu Sato & Yoshio Taguma

  2. Hotta Osamu Clinic, Rokutyounomeminamimachi 2-39, Wakabayashi-ku, Sendai, Miyagi, 984-0013, Japan

    Norio Ieiri & Osamu Hotta

Authors
  1. Norio Ieiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Osamu Hotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Toshinobu Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshio Taguma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Norio Ieiri.

About this article

Cite this article

Ieiri, N., Hotta, O., Sato, T. et al. Significance of the duration of nephropathy for achieving clinical remission in patients with IgA nephropathy treated by tonsillectomy and steroid pulse therapy. Clin Exp Nephrol 16, 122–129 (2012). https://doi.org/10.1007/s10157-011-0530-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-011-0530-1

Keywords

Search

Navigation